A
Adaptilens
Improving vision and the quality of life of cataract patients
About Adaptilens
Adaptilens is an innovative startup focused on revolutionizing the field of ophthalmology, specifically targeting the cataract surgery market. The company is developing the Accommodating Intraocular Lens (A-IOL), a groundbreaking biomimetic lens designed to restore vision to its youthful state. This advanced lens mimics the natural focusing ability of the eye, potentially offering a significant improvement over existing intraocular lenses used in cataract surgeries.
The company primarily serves ophthalmologists and their patients who are undergoing cataract surgery. By providing a superior alternative to current intraocular lenses, Adaptilens aims to enhance the quality of life for millions of individuals suffering from cataracts, a condition that affects a significant portion of the aging population.
Adaptilens operates in the highly specialized and competitive ophthalmology market. The company is currently in the development phase, with its A-IOL undergoing first-in-human trials. This phase is crucial for obtaining regulatory approval and moving towards commercial use.
The business model of Adaptilens is centered around the development, approval, and eventual commercialization of its innovative lens technology. The company has secured funding through a Series A round, following an earlier seed round led by Pillar VC and Accanto Partners. Additional financial support has come from awards such as the Harvard Innovation Challenge and the Massachusetts Life Sciences Center Initiative for Women Entrepreneurs.
Adaptilens generates revenue through investments and grants during its development phase. Once the A-IOL receives regulatory approval, the company will shift to a revenue model based on the sale of its lenses to medical institutions and ophthalmologists.
In summary, Adaptilens is poised to make a significant impact in the field of ophthalmology by offering a cutting-edge solution for cataract surgery. The company's focus on innovation, backed by a team of experienced professionals and strong financial support, positions it well for future success.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Brookline, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 73.4/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Ophthalmology, medical implants, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $18M | $70M | Pillar VC · 380 Cap · Accanto Partners · Perceptive Advisors | ↗ |
| SEED✓Equity / VC | Nov 2020 | $1.6M | $6.4M | Pillar VC · Accanto Partners | — |
Growth signals
Latest recorded traffic for Adaptilens is 340 monthly website visits, down 29.2% over the last three months. Adaptilens's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Pillar VC
Accanto Partners
Series A2 investors entered at this stage
Perceptive Advisors- 3C380 Cap
Other known investors2 additional known investors
MassChallenge
Xontogeny
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adaptilens on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adaptilens’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.